Study identifies a host of agents with anti-SARS-CoV-2 potential

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease 2019 (COVID-19), continues to spread worldwide. Over 96.97 million cases have been confirmed across 191 countries and territories, and over 2 million people have lost their lives.

Many studies have tested the effects of various drugs and agents in the past. To date, there is still no targeted antiviral treatment for COVID-19.

A team of researchers from Academia Sinica and the National University in Taiwan and the La Jolla Institute in the US evaluated the efficacy of 2,855 agents against SARS-CoV-2. They found that agents like mefloquine, nelfinavir, and extracts of plants such as Ganoderma lucidum (RF3) or Lingzi, Perilla frutescens, or Korean perilla, and Mentha haplocalyx or mentha, were found to be effective against SARS-CoV-2 infection in animal models.

The study

To arrive at the study findings, which were published in the Proceedings of the National Academy of Science of the United States of America (PNAS), the researchers utilized a cell-based infection assay to screen more than 3,000 agents used in humans and animals. From there, the team has identified 15 with antiviral activity.

The team used in vitro enzymatic assays alongside computer modeling to test and confirm the activity of the chosen agents against the viral protease and RNA polymerase of SARS-CoV-2.

The team used these agents by developing a challenge assay with hamsters. They identified five agents that can be used to develop new therapeutics to contain the current pandemic.

Cell-based study

The Vero E6 cell-based study has identified the 15 chemicals from a library of compounds approved for human and animal use. The team categorized the chemicals into five clusters – viral protease inhibitors, inhibitors of SARS-CoV-2 function, guanine analog, ion channel modulators, and ionophoric antibiotics.

The chemicals include nelfinavir, boceprevir, thioguanine, cepharanthine, emetine, moxidectin, ivermectin, mefloquine, ivacaftor, azelnidipine, penfluridol, dronedarone, salinomycin, monensin, and maduramicin.

Dose–response relationships of 15 selected antiviral compounds. Vero E6 cells were pretreated with compounds at indicated doses followed by SARS-CoV-2 infection for 48 h. The percentage of viral titer determined by antinucleocapsid antibody after drug treatment (red) and cell viability (blue) were measured and expressed as mean ± SD of at least three independent experiments.
Dose–response relationships of 15 selected antiviral compounds. Vero E6 cells were pretreated with compounds at indicated doses followed by SARS-CoV-2 infection for 48 h. The percentage of viral titer determined by antinucleocapsid antibody after drug treatment (red) and cell viability (blue) were measured and expressed as mean ± SD of at least three independent experiments.

Many Chinese herbal medicines and supplements were also tested, including species of Asterceae, Theaceae, Mentheae, and Lamiaceae.

The team found that several drugs like mefloquine, nelfinavir, and extracts of Ganoderma lucidum (RF3), Perilla frutescens, and Mentha haplocalyx were effective against SARS-CoV-2 infection.

The team also noted that since the safety and pharmacological characteristics of these drugs were already studied, the preclinical and clinical evaluation of the active compounds is expected to be faster. Hence, it can reduce the time, effort, and cost for further development of these agents.

Conclusion

The herbal compounds found to be effective in combating SARS-CoV-2 could be interesting sources to discover and develop new therapeutics that inhibit viral activity. These compounds may also be used in human trials to determine their safety and efficacy in patients with COVID-19.

While the vaccination campaign is rolling out in some countries, it is still important to determine drugs and agents to combat the pandemic. This way, those who do not have the vaccine yet may be assured of an effective treatment.

Source:
Journal reference:
Angela Betsaida B. Laguipo

Written by

Angela Betsaida B. Laguipo

Angela is a nurse by profession and a writer by heart. She graduated with honors (Cum Laude) for her Bachelor of Nursing degree at the University of Baguio, Philippines. She is currently completing her Master's Degree where she specialized in Maternal and Child Nursing and worked as a clinical instructor and educator in the School of Nursing at the University of Baguio.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Laguipo, Angela. (2021, January 22). Study identifies a host of agents with anti-SARS-CoV-2 potential. News-Medical. Retrieved on March 06, 2021 from https://www.news-medical.net/news/20210122/Study-identifies-a-host-of-agents-with-anti-SARS-CoV-2-potential.aspx.

  • MLA

    Laguipo, Angela. "Study identifies a host of agents with anti-SARS-CoV-2 potential". News-Medical. 06 March 2021. <https://www.news-medical.net/news/20210122/Study-identifies-a-host-of-agents-with-anti-SARS-CoV-2-potential.aspx>.

  • Chicago

    Laguipo, Angela. "Study identifies a host of agents with anti-SARS-CoV-2 potential". News-Medical. https://www.news-medical.net/news/20210122/Study-identifies-a-host-of-agents-with-anti-SARS-CoV-2-potential.aspx. (accessed March 06, 2021).

  • Harvard

    Laguipo, Angela. 2021. Study identifies a host of agents with anti-SARS-CoV-2 potential. News-Medical, viewed 06 March 2021, https://www.news-medical.net/news/20210122/Study-identifies-a-host-of-agents-with-anti-SARS-CoV-2-potential.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New evidence of SARS-CoV-2 spreading on planes